MORRISTOWN, N.J., July 6, 2015 /PRNewswire/ -- Moerae Matrix, a clinical stage biotechnology company focused on developing novel therapeutics that target inflammation and fibrosis, today announced the appointment of Bill Bradford, M.D., PhD, as Chief Medical Officer.
Dr. Bradford will lead the company's clinical development strategy and programs, which include a pipeline of therapies for pulmonary diseases and other inflammatory and fibrotic conditions. Bill is an accomplished strategist and scientist with extensive experience in the biopharma industry in various executive, clinical development, and medical affairs roles. Prior to joining Moerae, Dr. Bradford was Senior Fellow and previously SVP Clinical Science and Biometrics at InterMune, where he was instrumental in the development and regulatory approvals of pirfenidone (Esbriet™) for the treatment of Idiopathic Pulmonary Fibrosis.
"As a leader and widely-respected peer in the pulmonary community based on his pioneering development work in Idiopathic Pulmonary Fibrosis, Bill will be a valuable addition to the Moerae team as we move our platform of MAPKAP Kinase 2 inhibitors forward," said Cynthia Lander, PhD, Moerae's Chief Executive Officer. "Bill's strategic capabilities and experience are unparalleled. He will strengthen our corporate and clinical development and research efforts as we advance our lead drug, MMI-0100, for pulmonary disorders and other conditions, as well as progress our earlier stage pipeline."
"I am excited to be joining Moerae at this important time in the company's evolution as we prepare to advance our MMI-0100 clinical program into patients. MMI-0100, a selective inhibitor of MK2 that has demonstrated significant anti-inflammatory and anti-fibrotic activity in a variety of different preclinical models, has a potential role in the management of a number of major disease states that currently represent significant unmet medical needs, including Idiopathic Pulmonary Fibrosis," said Dr. Bradford. "I look forward to working with the talented team at Moerae to develop MMI-0100 and an impressive pipeline of compounds."
SOURCE Moerae Matrix, Inc.